Aptevo Therapeutics Stock
Aptevo Therapeutics Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Jeffrey G. Lamothe
- Employees
- 33
- Market cap
- $4 M
- IPO
- 20/07/2016
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company primarily focused on pioneering immunotherapeutic agents for a variety of cancer treatments across the United States. Its foremost investigational drug, APVO436, is a bispecific antibody crafted to engage T-cells, which is currently undergoing a Phase…
Aptevo Therapeutics stock: price history
1D
-4.7%
1W
-9.5%
1M
-5.8%
6M
-69.3%
YTD
-82.8%
1Y
-94.0%
2Y
-99.9%
5Y
-100.0%
10Y
-100.0%
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~3% weaker price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vsqueeze-release-v1.0 on 15/10/26. Not a buy or sell signal.Beta
What does this mean?
Volatility squeeze
BearishPrice swings had compressed unusually tight beforehand (volatility near a low) and are now releasing into a stronger move. Technical analysis views such tight phases as often preceding a bigger move.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Aptevo Therapeutics
Analyst assessment of Aptevo Therapeutics
0
STRONG BUY
3
BUY
0
HOLD
0
SELL
0
STRONG SELL
3
TOTAL · Buy
As of: 12/05/2022
Aptevo Therapeutics stock metrics
P/E
-0.01
P/B
0.32
EV/EBITDA
0.08
RETURN ON EQUITY
-105.2%
NET MARGIN
0.0%
DEBT/EQUITY
0.7
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
92.0%
FLOAT SHARES
1,146,836
AVG. DAILY VOLUME (30D)
68,299
Insider transactions (SEC)
Niederhuber John
Kunz Barbara Lopez
Abdun-Nabi Daniel
White Marvin L
White Marvin L
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Aptevo Therapeutics stock
What does Aptevo Therapeutics do?
Aptevo Therapeutics Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Jeffrey G. Lamothe, the company employs around 33 people.
The IPO was on 20/07/2016; the stock trades on NASDAQ under the ticker APVO.
What do analysts say about Aptevo Therapeutics stock?
3 analysts rate the stock, the consensus is Buy (as of 12/05/2022).
This is an external assessment, not a statement by Market Jury.
When does Aptevo Therapeutics report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly -3% stronger than usual.
Does Aptevo Therapeutics pay a dividend?
No, Aptevo Therapeutics currently does not pay a dividend.
Which stocks are comparable to Aptevo Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Aptevo Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Aptevo Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.